Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL

NCT02393859 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02393859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02393859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
November 10, 2015
Completion date
November 21, 2022
Enrollment
111 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, acute lymphoblastic